BioCentury | Feb 4, 2021
Management Tracks

Novo Foundation names Krogsgaard Thomsen CEO; plus Takeda’s Sequeira to become first woman to chair PhRMA and updates from Almirall, Twist, Oncosec and more

...Corp. (NASDAQ:TWST) promoted Siyuan Chen to CTO and Aaron Sato to CSO.Cytokine-based intratumoral immunotherapy play OncoSec Medical Inc....
...at Themis Bioscience GmbH, which Merck & Co. (NYSE:MRK) acquired last year. BC Staff Scenic Biotech B.V. Almirall S.A. OncoSec Medical Inc. OncoNano...
BioCentury | Nov 11, 2020
Product Development

Nov. 10 Quick Takes: Tezepelumab meets in asthma Phase III; plus a call for speedy trial results, updates on COVID vaccines from Sinovac, CureVac and more

...$8.80 (46%) to a first-day close of $27.80.OncoSec’s...
...IL-12, OMS ElectroImmunotherapy (ImmunoPulse)) Cryopraxis Cryobiology Ltd. Merck iRepertoire Inc. Amgen Inc. OncoSec Medical Inc. CureVac...
BioCentury | Oct 12, 2020
Management Tracks

Rivera joins Akili as CMO; plus moves at Polyneuron, Checkmate, CytomX, BIO, ProQR, Silence and OncoSec

...2021 to take a new position. The company has initiated a search for a U.S.-based CFO.OncoSec Medical Inc....
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...tumor microenvironment. Inovio Pharmaceuticals Inc. (NASDAQ:INO) and OncoSec Medical Inc....
...with AZ’s checkpoint inhibitor Imfinzi durvalumab, while OncoSec’s...
...A/S Iovance Biotherapeutics Inc. Medicenna Therapeutics Corp. Philogen S.p.A. Inovio Pharmaceuticals Inc. OncoSec Medical Inc. [MERGED]...
BioCentury | Feb 1, 2020
Company News

Management tracks: Trio of female exec appointments; plus FDA, Cell and Gene Therapy Catapult, SutroVax, Lundquist Institute, RedShift, NeoImmuneTech and more

...Inc. (NASDAQ:MRNA) hired Melanie Ivarsson as chief development officer. Bonstein was CFO and COO of OncoSec Medical Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:IMRN) 5/23/19 $2.0 $16.3 $13.0 -20% Guardant Health Inc. (NASDAQ:GH) 5/23/19 $319.5 $6,504.5 $7,908.9 22% OncoSec Medical Inc....
BioCentury | Jun 28, 2019
Preclinical News

OncoSec jumps into TNBC CAR T therapy via Dana-Farber deal

...a Dana-Farber antibody engineering expert and leveraging the institute’s cell manufacturing capabilities, cytokine therapeutics company OncoSec...
...explore new modalities that could synergize with their existing pipelines. In a deal announced Thursday, OncoSec...
...Tavo tavokinogene, OncoSec's DNA plasmid encoding IL-12. The company also markets electroporation devices. O'Connor said OncoSec...
BioCentury | Feb 8, 2019
Clinical News

Preliminary ORR 24% for Oncosec's Tavo plus Keytruda in Phase II for melanoma

...Co. Inc. (NYSE:MRK) led to an observed overall response rate (ORR) of 24%. This year, OncoSec...
...is a 20% ORR. Tavo is a DNA plasmid coding for IL-12 delivered via electroporation. OncoSec...
...accelerated approval in the U.S. in 2020 and seek conditional approval in Europe soon after. OncoSec Medical Inc....
BioCentury | Jan 26, 2018
Company News

Avacta, OncoSec combine technologies

...OncoSec Medical Inc. (NASDAQ:ONCS) partnered to combine Avacta’s Affimer protein platform, including its PD-L1 inhibitor AVA04, with OncoSec’s...
...Avacta Group plc (LSE:AVCT), Heslington, U.K. OncoSec Medical Inc. (NASDAQ:ONCS), San Diego, Calif. Business: Cancer Shannon Lehnbeuter Avacta Group plc OncoSec Medical Inc....
BioCentury | Jan 19, 2018
Clinical News

OncoSec reports preliminary Phase I data for ImmunoPulse IL-12 in TNBC

...a single agent led to "robust objective responses in ImmunoPulse IL-12 treated and untreated lesions." OncoSec...
...been treated in the trial, which is expected to enroll about 10 patients. This year, OncoSec...
...to treat TNBC. ImmunoPulse IL-12 is a DNA plasmid coding for IL-12 delivered via electroporation. OncoSec Medical Inc....
Items per page:
1 - 10 of 73
BioCentury | Feb 4, 2021
Management Tracks

Novo Foundation names Krogsgaard Thomsen CEO; plus Takeda’s Sequeira to become first woman to chair PhRMA and updates from Almirall, Twist, Oncosec and more

...Corp. (NASDAQ:TWST) promoted Siyuan Chen to CTO and Aaron Sato to CSO.Cytokine-based intratumoral immunotherapy play OncoSec Medical Inc....
...at Themis Bioscience GmbH, which Merck & Co. (NYSE:MRK) acquired last year. BC Staff Scenic Biotech B.V. Almirall S.A. OncoSec Medical Inc. OncoNano...
BioCentury | Nov 11, 2020
Product Development

Nov. 10 Quick Takes: Tezepelumab meets in asthma Phase III; plus a call for speedy trial results, updates on COVID vaccines from Sinovac, CureVac and more

...$8.80 (46%) to a first-day close of $27.80.OncoSec’s...
...IL-12, OMS ElectroImmunotherapy (ImmunoPulse)) Cryopraxis Cryobiology Ltd. Merck iRepertoire Inc. Amgen Inc. OncoSec Medical Inc. CureVac...
BioCentury | Oct 12, 2020
Management Tracks

Rivera joins Akili as CMO; plus moves at Polyneuron, Checkmate, CytomX, BIO, ProQR, Silence and OncoSec

...2021 to take a new position. The company has initiated a search for a U.S.-based CFO.OncoSec Medical Inc....
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...tumor microenvironment. Inovio Pharmaceuticals Inc. (NASDAQ:INO) and OncoSec Medical Inc....
...with AZ’s checkpoint inhibitor Imfinzi durvalumab, while OncoSec’s...
...A/S Iovance Biotherapeutics Inc. Medicenna Therapeutics Corp. Philogen S.p.A. Inovio Pharmaceuticals Inc. OncoSec Medical Inc. [MERGED]...
BioCentury | Feb 1, 2020
Company News

Management tracks: Trio of female exec appointments; plus FDA, Cell and Gene Therapy Catapult, SutroVax, Lundquist Institute, RedShift, NeoImmuneTech and more

...Inc. (NASDAQ:MRNA) hired Melanie Ivarsson as chief development officer. Bonstein was CFO and COO of OncoSec Medical Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:IMRN) 5/23/19 $2.0 $16.3 $13.0 -20% Guardant Health Inc. (NASDAQ:GH) 5/23/19 $319.5 $6,504.5 $7,908.9 22% OncoSec Medical Inc....
BioCentury | Jun 28, 2019
Preclinical News

OncoSec jumps into TNBC CAR T therapy via Dana-Farber deal

...a Dana-Farber antibody engineering expert and leveraging the institute’s cell manufacturing capabilities, cytokine therapeutics company OncoSec...
...explore new modalities that could synergize with their existing pipelines. In a deal announced Thursday, OncoSec...
...Tavo tavokinogene, OncoSec's DNA plasmid encoding IL-12. The company also markets electroporation devices. O'Connor said OncoSec...
BioCentury | Feb 8, 2019
Clinical News

Preliminary ORR 24% for Oncosec's Tavo plus Keytruda in Phase II for melanoma

...Co. Inc. (NYSE:MRK) led to an observed overall response rate (ORR) of 24%. This year, OncoSec...
...is a 20% ORR. Tavo is a DNA plasmid coding for IL-12 delivered via electroporation. OncoSec...
...accelerated approval in the U.S. in 2020 and seek conditional approval in Europe soon after. OncoSec Medical Inc....
BioCentury | Jan 26, 2018
Company News

Avacta, OncoSec combine technologies

...OncoSec Medical Inc. (NASDAQ:ONCS) partnered to combine Avacta’s Affimer protein platform, including its PD-L1 inhibitor AVA04, with OncoSec’s...
...Avacta Group plc (LSE:AVCT), Heslington, U.K. OncoSec Medical Inc. (NASDAQ:ONCS), San Diego, Calif. Business: Cancer Shannon Lehnbeuter Avacta Group plc OncoSec Medical Inc....
BioCentury | Jan 19, 2018
Clinical News

OncoSec reports preliminary Phase I data for ImmunoPulse IL-12 in TNBC

...a single agent led to "robust objective responses in ImmunoPulse IL-12 treated and untreated lesions." OncoSec...
...been treated in the trial, which is expected to enroll about 10 patients. This year, OncoSec...
...to treat TNBC. ImmunoPulse IL-12 is a DNA plasmid coding for IL-12 delivered via electroporation. OncoSec Medical Inc....
Items per page:
1 - 10 of 73